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CD55 upregulation in astrocytes by statins
as potential therapy for AQP4-IgG
seropositive neuromyelitis optica
Lukmanee Tradtrantip1, Tianjiao Duan1,2, Michael R. Yeaman3,4 and Alan S. Verkman1*
Abstract
Background: Neuromyelitis optica spectrum disorder (herein called NMO) is an inflammatory demyelinating disease
that can be initiated by binding of immunoglobulin G autoantibodies (AQP4-IgG) to aquaporin-4 on astrocytes,
causing complement-dependent cytotoxicity (CDC) and downstream inflammation. The increased NMO pathology in
rodents deficient in complement regulator protein CD59 following passive transfer of AQP4-IgG has suggested the
potential therapeutic utility of increasing the expression of complement regulator proteins.
Methods: A cell-based ELISA was developed to screen for pharmacological upregulators of endogenous CD55 and
CD59 in a human astrocyte cell line. A statin identified from the screen was characterized in cell culture models and
rodents for its action on complement regulator protein expression and its efficacy in models of seropositive NMO.
Results: Screening of ~ 11,500 approved and investigational drugs and nutraceuticals identified transcriptional
upregulators of CD55 but not of CD59. Several statins, including atorvastatin, simvastatin, lovastatin, and fluvastatin,
increased CD55 protein expression in astrocytes, including primary cultures, by three- to four-fold at 24 h, conferring
significant protection against AQP4-IgG-induced CDC. Mechanistic studies revealed that CD55 upregulation involves
inhibition of the geranylgeranyl transferase pathway rather than inhibition of cholesterol biosynthesis. Oral atorvastatin
at 10–20mg/kg/day for 3 days strongly increased CD55 immunofluorescence in mouse brain and spinal cord and
reduced NMO pathology following intracerebral AQP4-IgG injection.
Conclusion: Atorvastatin or other statins may thus have therapeutic benefit in AQP4-IgG seropositive NMO by
increasing CD55 expression, in addition to their previously described anti-inflammatory and immunomodulatory
actions.
Keywords: NMO, Aquaporin-4, CD55, Astrocyte, Complement-dependent cytotoxicity, Statins
Introduction
Neuromyelitis optica spectrum disorder (herein called
NMO) is an inflammatory demyelinating disease of the cen-
tral nervous system. In seropositive NMO, immunoglobulin
G autoantibodies against water channel aquaporin-4
(AQP4), called AQP4-IgG, bind to AQP4 on astrocytes and
cause cytotoxicity largely by a complement-dependent mech-
anism [1–5]. Consequent inflammation, blood-brain barrier
disruption, and oligodendrocyte injury result in demyelin-
ation and neurological deficit. Current therapy for NMO
includes immunosuppressants, B cell depletion, and plasma
exchange, and new therapeutics are in the development
pipeline that target complement, cytokines, immune cells,
and AQP4-IgG binding to astrocyte AQP4 [6–9].
Evidence for an important role of complement in sero-
positive NMO includes vasculocentric deposition of acti-
vated complement in NMO-affected human tissues [2, 10–
12], complement-dependent NMO pathology in rodents
following passive transfer of AQP4-IgG [13–15], and effi-
cacy of the C5 complement inhibitor eculizumab in a
preliminary clinical trial [16]. Additional evidence includes
the increased NMO pathology in mice and rats lacking
complement regulator protein CD59 following passive
transfer of AQP4-IgG into the central nervous system [15,
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17, 18]. NMO therapeutics that target components of the
complement activation pathway can be associated with sig-
nificant infectious and autoimmune side effects, as can
agents that target B cells or other immune effectors [19,
20]. As an alternative approach, as motivated by the conse-
quences of CD59 knockout [15, 17, 18], inhibition [15], and
overexpression [21] in experimental animal models of
NMO, here we investigate the therapeutic utility of
pharmacological upregulation of complement regulator
proteins in astrocytes.
We report a high-throughput screen to identify small
molecule transcriptional upregulators of CD55 and
CD59, the major complement regulator proteins in as-
trocytes. For screening, a human astrocyte-derived cell
line was identified that endogenously expressed low to
moderate levels of CD55 and CD59. Compounds emer-
ging from the screen included statins, which were char-
acterized for their mechanism of action in increasing
CD55 expression in astrocytes and for their potential
therapeutic utility in NMO.
Materials and methods
Materials
Purified recombinant AQP4-IgG (rAb-53, refs. [22, 23])
was provided by Dr. Jeffrey Bennett (Univ. Colorado,
Denver). Human complement was purchased from
Innovative Research (Novi, MI) and human (control) IgG
from Pierce Biotechnology (Rockford, IL). GGTI-286 was
purchased from Calbiochem (San Diego, CA), fasudil from
Abcam (Cambridge, MA), and zaragozic acid A from
Cayman Chemical Co. (Ann Arbor, MI). All other chemi-
cals were purchased from Sigma-Aldrich (St. Louis, MO).
Cell culture
U-251MG (NCI) and U-373MG (ATCC HTB-17) cells
were cultured in Minimum Essential Medium (MEM)
Eagle’s with Earle’s BSS supplemented with 10% fetal bo-
vine serum, 2mM glutamine, 1mM sodium pyruvate,
non-essential amino acid, 100 U/mL penicillin, and
100 μg/mL streptomycin at 37 °C in 5% CO2 95% air.
U-87MG (ATCC HTB-14) cells were cultured in the same
medium but without sodium pyruvate and non-essential
amino acids.
Screening procedures
U-251MG cells were plated in black 96-well plates with
a clear plastic bottom (Corning Inc., Corning, NY) at a
density of 20,000 cells per well. Eighty wells contained
test compounds, and the first and last columns of each
plate were used for vehicle control (no test compound)
and negative control (cells treated with 0.5 U/mL
PI-PLC (Invitrogen, Carlsbad, CA)). After overnight
growth to reach confluence, cells were washed twice
with PBS, then 50 μL of culture medium was added to
each well. Test compounds were added (0.5 μL of 2.5
mM DMSO stock) to each well to give 25 μM final
concentration and incubated with cells at 37 °C over-
night. After washing twice, cells were fixed in 4% para-
formaldehyde for 15 min and then blocked with 1% BSA
for 30min. Then, 50 μL of a pre-mixed solution of
anti-human CD55 antibody (NaM16-4D3, 1:200, Santa
Cruz Biotechnology, Dallas, TX), anti-human CD59 anti-
body (YTH53, 1:200, Santa Cruz Biotechnology), Alexa
Fluor-555 labeled goat anti-rat (A-21434, Invitrogen), and
Alexa Fluor-647-labeled donkey anti-mouse IgG second-
ary antibody (A-31571, Invitrogen) (1:500 dilution) was
then added and incubated with cells for 3 h. After washing
four times with PBS containing 0.05% Tween-20, fluores-
cence was measured using a plate reader at excitation/
emission wavelengths of 555/565 and 650/665 nm.
Relative expression was computed as follows: (com-
pound-negative control)/(DMSO-negative control).
Astrocyte cell culture
Primary astrocyte cultures were generated from the brain
cortex of neonatal rats at day 7 post-birth, as described [24]
with modification. Briefly, the cerebral hemispheres were iso-
lated and cortical tissue was minced and incubated for 15
min at 37 °C in 0.25% trypsin-EDTA. Dissociated cells were
centrifuged and resuspended in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% FBS and 1% penicillin/
streptomycin, and grown at 37 °C in a 5% CO2 incubator.
After confluence (8–10 days), flasks were shaken in a rotator
at 180 rpm overnight to purify astrocytes and medium was
replaced with DMEM containing 3% FBS and 0.25mM
dibutyryl cAMP. Cultures were maintained for an additional
2 weeks. Cultures contained > 95% astrocytes as seen by
positive glial fibrillary acidic protein (GFAP) (AB5541,
1:1000, Millipore) immunofluorescence.
Complement-dependent cytotoxicity (CDC)
Astrocyte cultures were trypsinized, plated onto 96-well
plates at 20,000 cells/well, and grown for 48 h. Human
complement and AQP4-IgG were added in Hank’s
balanced salt solution (HBSS, pH 7.2; Invitrogen), and
cells were incubated at 37 °C for 2 h for cytotoxicity
measurement by the Alamar Blue assay (Invitrogen) as
described [25]. For C3d immunostaining, astrocyte
cultures were exposed to AQP4-IgG and C6-depleted
serum for 2 h, then washed and fixed with 4% parafor-
maldehyde (PFA). C6-depleted serum was used to
visualize complement activation without cell lysis from
membrane attack complex formation. After blocking,
cells were incubated with anti-human C3d (1:50, Santa
Cruz Biotechnology), then washed and incubated with
Alexa-Fluor 555-conjugated secondary antibody for 1 h
(5 μg/mL, Invitrogen).
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Intracerebral injection model
Mice were housed and bred in the UCSF Laboratory
Animal Resource Center. AQP4-IgG (7.5 μg) was deliv-
ered by intracerebral injection as described [13, 26] with
modification. Adult wild-type male mice (age 8–10
weeks; weight 25–30 g) in a CD1 genetic background
were anesthetized with ketamine (100 mg/kg) and xyla-
zine (10 mg/kg) and mounted on a stereotaxic frame. A
midline scalp incision was made, and a burr hole of
1-mm diameter was drilled on each side of the skull 0.5
mm anterior and 2 mm lateral to the bregma. A glass
pipette with 40-μm diameter tip was inserted at a depth of
3 mm to infuse 7.5 μg AQP4-IgG (or control IgG) and
1 μL human complement in a total volume of 3 μL over
10min by pressure injection. After injection, the glass pip-
ette was kept in place for 10min before slow withdrawal
over 5min to prevent leaking. At day 6, mice were deeply
anesthetized and transcardially perfused with 200mL hep-
arinized PBS and 200mL of 4% PFA in PBS. Brains were
removed and post-fixed for 4 h in 4% PFA and cryopro-
tected in 20% sucrose. Serial frozen coronal sections
(thickness 7 μm) were cut on a cryostat (Leica CM 1900,
Leica Biosystem, Inc., Buffalo Grove, IL).
Immunofluorescence
U-251MG and primary astrocyte cultures were grown
on glass coverslips for 24 h, then incubated with test
compound for another 24 h. Cells were then fixed in 4%
PFA for 15 min. After blocking with 1% BSA in PBS,
cells were incubated with primary antibody: anti-human
CD55 (NaM16-4D3, 1:100), anti-human CD59 (YTH53,
1:700), anti-rat CD55 (RDIII-7 1:50, Hycult Biotech,
Plymouth Meeting, PA), anti-rat CD59 (clone TH9, 1:50,
LifeSpan Biosciences, Seattle, WA), or anti-human C3d
(003-05, 1:50, Santa Cruz Biotechnology) for 1 h at room
temperature. Cells were then washed with PBS and incu-
bated with the appropriate species-specific Alexa
Fluor-conjugated secondary antibody for 1 h (Alexa
Fluor-488-labeled goat anti-rat (A-11006) and Alexa
Fluor-555 labeled goat anti-mouse IgG secondary anti-
body (A-21424), 5 μg/mL each, Invitrogen). Slides were
washed four times with PBS and mounted using
Prolong™ Gold antifade reagent with DAPI (Invitrogen)
counterstain for visualization of immunofluorescence on
a Leica fluorescence microscope or Nikon confocal
microscope.
Frozen sections of mouse brain, spinal cord, optic nerve,
and skeletal muscle were post-fixed in 4% PFA for 5min
and incubated in blocking solution as described [18, 27].
Slides were then incubated for 2 h with antibodies against
CD55 (NaM16-4D3, 1:50), CD59 (7A6, 2 μg/mL, Hycult
Biotech), AQP4 (H-80, 1:200, Santa Cruz Biotechnology),
C3d (003-05, 1:100, Santa Cruz Biotechnology), C5b-9
(aE11, 1:100, Santa Cruz Biotechnology), myelin basic
protein (MBP, C-16, 1:100, Santa Cruz Biotechnology),
ionized calcium-binding adaptor molecule 1 (Iba-1,
019-19741, 1:1000, Wako, Richmond, VA), or endothelial
cell marker (isolectin B4-FITC conjugated,
ALX-650-001F-MC05, 10 μg/mL, Enzo Life Sciences,
Farmingdale, NY), followed by the appropriate secondary
antibody for 1 h (Alexa Fluor-488 labeled donkey
anti-rabbit (A-21206), Alexa Fluor-488-labeled donkey
anti-goat (A-11055), Alexa Fluor-555-labeled donkey
anti-mouse (A-31570), and Alexa Fluor-555-labeled
donkey anti-rabbit IgG secondary antibody (A-31572),
5 μg/mL each, Invitrogen).
Image analysis
Fluorescence signal was quantified using ImageJ (NIH).
For measurements in cell cultures, mean pixel fluores-
cence intensity was measured using full-field images, with
subtraction of background as determined using three or
more areas devoid of cells. Relative fluorescence signal
was reported as the ratio of drug-treated cells to
DMSO-treated cells. Full-field images were also analyzed
for measurements of CD55 immunofluorescence in
tissues, in which background was determined after thresh-
olding to exclude ~ 25% of the brightest pixels; robustness
of the analysis was verified in an independent analysis that
used thresholding to identify regions of interest around
cell structures (not reported). For mouse brain, quantifi-
cation of lesion area was done by image analysis as
described [17] in which AQP4 and MBP immunone-
gative areas, and C5b-9 immunopositive areas, were
defined by hand and areas quantified using ImageJ.
RT-PCR
cDNA from reverse-transcribed mRNA isolated from
U-251MG cells was PCR amplified with the following
primers: 5′-TGACTGTGGCCTTCCCCCAGAT-3′ and
5′-GTGTTACATGAGAAGGAGATGG-3′, 168–640 (CD
55), and 5′-TGACGGGGTCACCCACACTGTGCCCAT
CTA-3′ and 5′-CTAGAAGCATTGCGGTGGACGATG
GAG GG-3′, 478–1128 (β-actin) [28] in an Applied Biosys-
tems 2720 Thermal Cycler (Applied Biosystems, Foster City,
CA). PCR conditions were at 94 °C for 5min followed by 30
cycles of 94 °C for 30 s and 54 °C for 1min, with final exten-
sion at 72 °C for 7min. After amplification, the PCR prod-
ucts were run on a 2% agarose gel with ethidium bromide
and photographed by Axygen Gel® Documentation System:
Model GDBL-1000 (Fisher Scientific, Waltham, MA). The
images were quantified using ImageJ; relative mRNA expres-
sion was calculated by the ratio of target gene expression to
reference gene (β-actin).
Statistics
Data are presented as mean ± SEM. Statistical analysis
was performed using Prism 5 GraphPad Software
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package (San Diego, CA). Normal distribution of all data
was confirmed by the Shapiro-Wilk test. Statistical com-
parisons were made using unpaired Student’s t test for
comparisons between two groups. Differences were con-
sidered significant at P < 0.05 (* = P ≤ 0.05, ** = P ≤ 0.01).
Results
Complement regulator screen
An assay suitable for high-throughput screening was
established to identify compounds that upon many
hours of incubation could increase the expression of
CD55 or CD59 in astrocytes. Because compounds were
sought that acted by a transcriptional mechanism, a
human astrocyte cell line was chosen with low or mod-
erate endogenous expression of CD55 and CD59 in
order to produce measurable signals in the screening
assay and in which baseline expression is sufficiently low
to permit upregulation. The immortalized human astro-
cyte cell lines U-87MG, U-251MG, and U-373MG were
tested. CD55 and CD59 immunofluorescence showed
different levels of expression in the three cell lines
(Fig. 1). Little fluorescence was seen in control cells fol-
lowing treatment with PI-PLC, which cleaves the extra-
cellular antigen-containing portions of CD55 and CD59.
U-373MG cells were not used for screening because of
their very low CD55 immunofluorescence. U-87MG
cells were not used for screening because they detached
easily during washing steps and because of their high
baseline CD55 expression that is likely to be near or at
the maximum level. U-251MG cells were selected for
screening based on their moderate expression of CD55
and CD59, which provided a measurable signal with
sufficient room for upregulation.
Figure 2a diagrams the cell-based screening assay in
which suitable antibodies were chosen for two-color de-
tection of CD55 and CD59 expression in the same cells
without cross-talk. The assay used a mouse anti-human
primary CD55 antibody and rat anti-human primary
CD59 antibody, with appropriate fluorescent secondary
antibodies. Examples of assay data are shown in Fig. 2b.
PI-PLC strongly reduced fluorescence for both CD55
and CD59 detection, demonstrating assay specificity;
Z-factor analysis showed assay reliability (Z’-factors 0.52
and 0.48, respectively). The assay did not include “posi-
tive controls” because there are no known compounds
that upregulate CD55 or CD59 expression in astrocytes.
Screening was done on collections of approved and in-
vestigational drugs, and nutraceuticals, recognizing the
benefits of drug repurposing for human clinical testing.
The screen, which was done at a drug/nutraceutical con-
centration of 25 μM, did not produce compounds that
significantly increased CD59 expression (cut-off
1.5-fold); however, compounds that increased CD55 ex-
pression by > 2-fold were identified, including several
statins (atorvastatin, simvastatin, lovastatin, mevastatin)
and phorbal 12-myristate 13-acetate. Because of their
generally good brain penetration and established safety
profile, further studies were done on statins. Figure 2c
shows chemical structures of FDA-approved statins that
were investigated, each of which contains a dihydroxy-
heptanoic acid component that is structurally similar to
the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG
CoA) substrate in the cholesterol biosynthetic pathway.
CD55 upregulation by statins
U-251MG cells were incubated with each of the statins
at 25 μM for 24 h. Figure 3a shows representative CD55
and CD59 immunofluorescence, with the fold-increased
expression summarized in Fig. 3b. Most statins substan-
tially increased CD55 expression, though none of the
compounds increased CD59 expression. The broad ac-
tivity of statins on CD55 expression suggests action on
their well-known target, HMG-CoA reductase, rather
than off-target effects. The lack of effect of pravastatin
may be related to its high hydrophilicity and consequent
low cell permeability. Atorvastatin, which is the seventh
most commonly prescribed drug in the US, was selected
for further studies because of its penetration into the
Fig. 1 Complement regulator protein expression in human astrocyte cell lines. CD55 and CD59 immunofluorescence in U-87MG, U-251MG, and
U-373MG cells. As control, cells were treated with PI-PLC to cleave the extracellular domains of CD55 and CD59. Representative of two sets
of experiments
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central nervous system [29, 30], as well as its favorable im-
munosuppressive and immunomodulatory actions [31, 32],
which are of potential therapeutic benefit in NMO.
Atorvastatin concentration-dependence data for CD55 up-
regulation in U-251MG cell cultures showed an EC50 of 1–
2 μM at 24-h incubation time (Fig. 4a). A time course study
at 5 μM atorvastatin showed slow onset of action, with a
50% increase in CD55 expression at 8–16 h, which is consist-
ent with a transcriptional upregulation mechanism (Fig. 4b).
In support of a transcriptional mechanism, RT-PCR showed
significant increased CD55 transcript in U-251MG cells
treated for 48 h with 1 μM atorvastatin, with comparable
β-actin transcript (Fig. 4c) (fold increase comparing with vs.
without atorvastatin, 1.6 ± 0.1, SEM, n= 3, P < 0.01). Cyclo-
heximide block of protein synthesis largely prevented the
increased CD55 expression by atorvastatin (Fig. 4d).
Mechanism of CD55 upregulation by atorvastatin
Statins inhibit cholesterol biosynthesis as well as the
formation of isoprenoid intermediates farnesyl
pyrophosphate (farnesyl-PP) and geranylgeranyl pyro-
phosphate (geranylgeranyl-PP), which affects post-
translational modification of a variety of signaling
proteins, including small GTPase RhoA, Cdc42, Rac1,
Rab, and heterotrimeric G proteins (Fig. 5a). Selective
modulators of components of the acetyl-CoA signal-
ing pathway were tested for their effects on CD55
expression. As shown in Fig. 5b and c, inclusion of
mevalonic acid (MVA) with atorvastatin for 24 h pre-
vented the atorvastatin effect, supporting the conclu-
sion that atorvastatin upregulation of CD55 involves
inhibition of HMG-CoA reductase, as mevalonate
bypasses the enzyme block. The squalene synthase in-
hibitor zaragozic acid did not increase CD55 expression,
indicating that the atorvastatin effect is not related to its
cholesterol-lowering action. Geranylgeraniol (GGOH), an
alcohol precursor of geranylgeranyl pyrophosphate (gera-
nylgeranyl-PP), largely blocked the atorvastatin-induced
CD55 upregulation, suggesting that action of atorvastatin
on the geranylgeranyl transferase pathway is responsible
A
B
C
Fig. 2 Screen for compounds that increase cell surface expression complement regulator proteins. a Schematic of 2-color cell-based ELISA for
detection of cell surface CD55 and CD59 expression on U-251MG cells. b Examples of primary screen data as measured in 96-well plate format
for immunodetection of CD55 (left) and CD59 (right). c Chemical structures of statins tested for CD55 upregulation
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for CD55 upregulation. In support of this conclusion, the
geranylgeranyl transferase inhibitor GGTI-286 (in the ab-
sence of atorvastatin) recapitulated the CD55 upregulation
seen with atorvastatin. The RhoA inhibitor fasudil did not
increase CD55 expression.
Atorvastatin increases CD55 expression in astrocyte
cultures and mouse brain
Atorvastatin upregulation of CD55 was investigated in
primary astrocyte cultures and in mice in vivo. Primary
astrocyte cultures were generated from neonatal rat
brains and differentiated by inclusion of dibutyryl cAMP
in the culture medium. Atorvastatin for 24 h increased
CD55 expression by up to ~ 3-fold, without significant
effect on CD59 expression (Fig. 6a). CD55 immunofluor-
escence showed a somewhat heterogeneous response from
cell to cell, both in CD55 expression at baseline and after
atorvastatin treatment. To determine whether CD55
upregulation in rat astrocyte cultures was protective
against complement-dependent cytotoxicity, cytotoxicity
was measured in control cells and cells incubated for 24 h
with atorvastatin prior to addition of AQP4-IgG and hu-
man complement. Atorvastatin significantly reduced cyto-
toxicity in a concentration-dependent manner (Fig. 6b).
C3d immunofluorescence of atorvastatin-treated astrocyte
cultures exposed to AQP4-IgG and C6-depleted comple-
ment was greatly reduced (Fig. 6b, inset), consistent with
the cytoprotective action of atorvastatin.
For experiments in vivo, mice were orally administered
atorvastatin at 10 mg/kg daily for 3 days, a dose regimen
similar to that used in prior in vivo brain studies in mice
[33–35]. CD55 immunofluorescence showed increased
CD55 immunofluorescence in the brain, optic nerve,
and spinal cord of atorvastatin-treated mice, though no
significant effect in skeletal muscle (Fig. 6c–e). CD59 ex-
pression was similar in control and atorvastatin-treated
mouse brain (Fig. 6c, left). The pattern of CD55 expres-
sion in atorvastatin-treated mouse brain was similar to
A
B
Fig. 3 Statins upregulate astrocyte CD55. a CD55 and CD59 immunofluorescence in U-251MG cells after 24-h treatment with statins at 20 μM. PI-PLC control
provided to show background fluorescence. b Summary of relative fluorescence as a measure of CD55 and CD59 cell surface expression, normalized to unity
in the absence of statins (mean± SEM, n=7, **P< 0.01, unpaired Student’s t test, compared with DMSO vehicle)
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that of AQP4, the astrocyte target of NMO autoantibody
(Fig. 6c, right) and that of an endothelia cell marker
(FITC-Isolectin B4) (Fig. 6f ); however, by light micros-
copy the relative increase in CD55 expression in astro-
cytes versus endothelia and other brain cells cannot be
resolved. The expression of AQP4 in central nervous
system tissues and skeletal muscle was similar in the
control and atorvastatin-treated mice (Fig. 6c–e).
Atorvastatin reduces pathology in an experimental
mouse model of NMO
Atorvastatin efficacy in reducing NMO pathology was
tested in an established experimental animal model of
NMO. As diagrammed in Fig. 7a, mice received atorva-
statin at 20 mg/kg daily for 3 days prior to intracerebral
injection of AQP4-IgG and human complement, with
control mice receiving saline instead of atorvastatin [13,
26, 36]. Atorvastatin was continued daily until sacrifice
on day 6 at which time brains were processed for im-
munofluorescence. Figure 7b shows reduced loss of
AQP4 and MBP, and reduced Iba-1 immunofluores-
cence, in the brain of atorvastatin-treated mice in a re-
gion surrounding the AQP4-IgG injection site compared
with vehicle-treated mice. These findings demonstrate
reduced astrocytopathy (AQP4), myelin loss (MBP), and
inflammation (Iba-1) with atorvastatin treatment. Lesion
size, as quantified by the areas of AQP4 and MBP loss,
was significantly reduced in atorvastatin-treated mice
(Fig. 7d). There was also an increase in immunofluores-
cence of markers of complement activation (C3d, C5b-9)
(Fig. 7c, d) and inflammation (Iba-1) (Fig. 7d).
Discussion
The purpose of this study was to identify a drug or nutra-
ceutical that increases the expression of complement regu-
lator protein(s) in astrocytes, for possible repurposing in
A
B
C D
Fig. 4 Concentration-dependence and kinetics of atorvastatin upregulation of astrocyte CD55 expression. a Atorvastatin concentration-dependence in
U-251MG cells following 24-h incubation. Representative immunofluorescence shown at the left and summary at the right (mean ± SEM, n= 7, *P< 0.05,
**P< 0.01, unpaired Student’s t test, compared with DMSO). b Time course of CD55 upregulation following incubation with 5 μM atorvastatin.
Representative immunofluorescence shown at the left and summary at the right (mean ± SEM, n= 7, *P< 0.05, **P< 0.01, unpaired Student’s t test,
compared with 0 h). c RT-PCR of CD55 and β-actin transcript expression following 48-h incubation of U-251MG cells with 1 μM atorvastatin. d CD55
immunofluorescence in U-251MG cell following 24-h incubation with 1 μM atorvastatin in the absence or presence of 3 μg/mL cycloheximide.
Representative of two sets of experiments
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NMO. The motivation for this work is the central import-
ance of complement-mediated cytotoxicity in AQP4-IgG
seropositive NMO, and the predicted importance, as dem-
onstrated in experimental animal models [15, 17, 18] and
by theoretical considerations [37], of complement regulator
proteins in modulating complement action on target cells.
Though there has been considerable research on comple-
ment mechanisms in NMO pathogenesis and on the devel-
opment and testing of complement-targeted therapeutics
[16, 25, 38], there has been relatively little work on comple-
ment regulator proteins in NMO. Increasing the expres-
sion or activity of complement regulator proteins on target
cells is a logical extension of complement inhibitor therapy
for NMO, with the potential advantage of avoiding the im-
munosuppressive actions of global complement inhibition
and their concomitant side effects. We found evidence
here for atorvastatin as a transcriptional upregulator of
CD55 in astrocytes by a mechanism that involves the gera-
nylgeranyl transferase pathway. The demonstrated conse-
quences of CD55 upregulation included inhibition of
complement-dependent cytotoxicity in astrocyte cultures
in vitro and reduced pathology in an experimental mouse
model of NMO in vivo.
Various physiological factors and drugs have been
reported to increase expression of complement regu-
lator proteins in human endothelial cells in the um-
bilical vein, skin, and aorta, which was proposed to
have relevance to inflammatory diseases involving
complement, including atherosclerosis and rheumatoid
arthritis [39–43]. Physiological factors, including
TNF-α, interferon-γ, and basic fibroblast growth
factor (bFGF), were reported to increase CD55 ex-
pression by a protein kinase C (PKC)-independent
pathway, whereas the vascular endothelial growth
factor (VEGF) was reported as PKC-dependent [39,
40, 42]. Drugs including atorvastatin and simvastatin
have been reported to increase complement regulator
protein expression in endothelia (41, 43), which was
proposed to explain the anti-inflammatory effect of
statins on the cardiovascular system apart from their
cholesterol-lowering action [44, 45].
Statins have pleotropic biological actions, several of
which are of a potential benefit in NMO. Statin inhib-
ition of HMG-CoA reductase blocks cholesterol biosyn-
thesis, its well-described action as a lipid-lowering
drug. Statins also inhibit biosynthesis of the isoprenoid
A
C
B
Fig. 5 Mechanism of CD55 upregulation by atorvastatin. a Schematic of cholesterol biosynthesis pathway and sites of action of indicated
agonists and inhibitors. Inhibitors color coded in red and activators in green. b CD55 immunofluorescence in U-251MG cells following 24-h
incubation with indicated compounds. c Summary of relative fluorescence (mean ± SEM, n = 7, *P < 0.05, **P < 0.01, unpaired Student’s t test,
comparison group as indicated)
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intermediates farnesyl pyrophosphate and geranylgera-
nyl pyrophosphate [31, 44]. Statin-induced upregulation
of CD55 in endothelial cells, and consequent protection
against complement-mediated injury, was reported
to involve inhibition of geranylgeranyl transferase
(GGTase) and RhoA [41, 46]. The mechanistic studies
here in Fig. 5b suggest that CD55 upregulation by atorva-
statin in astrocytes also involves GGTase inhibition. Ator-
vastatin has also been reported to cause CD59
upregulation in hypoxia in a model of rheumatoid arthritis
by a mechanism involving nitric oxide-dependent GGTase
inhibition [43].
A
C
D
E F
B
Fig. 6 Atorvastatin increases CD55 expression in primary astrocyte cultures and murine brain. a Astrocyte cultures were incubated with atorvastatin for 24 h.
Representative immunofluorescence shown in the left panel and summary data in the right panel (mean± SEM, n=6, *P<0.05, **P< 0.01, unpaired Student’s
t test, compared with DMSO (0 μM)). b Complement-dependent cytotoxicity in murine astrocyte cultures exposed to 5% human complement and 20 μg/mL
AQP4-IgG following 24-h incubation with atorvastatin (or vehicle control) (mean± SEM, n=4, *P< 0.05, **P<0.01, unpaired Student’s t test, compared with
DMSO (0μM)). Inset indicates C3d immunofluorescence in cells exposed to AQP4-IgG and c6-depleted complement. c (left) CD55 or CD59 (red) and AQP4
(green) immunofluorescence in cerebral cortex of control and atorvastatin-treated (10mg/kg daily for 3 days) mice. (right) Higher magnification micrographs
showing colocalization of AQP4 and CD55. d CD55 and AQP4 immunofluorescence of the spinal cord, optic nerve, and skeletal muscle from control and
atorvastatin-treated mice. Representative of four mice per group. e Summary of relative fluorescence as a measure of AQP4 and CD55 cell surface expression,
normalized to unity in the absence of atorvastatin (mean± SEM, n=6, **P< 0.01, unpaired Student’s t test, compared with saline). f FITC-Isolectin B4 (green)
and CD55 (red) immunofluorescence in cerebral cortex of control and atorvastatin-treated mice. Representative of four mice per group
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Several GGTase inhibitors (GGTIs) are in development
as potential anticancer drugs [47–49]. GGTI-286, a po-
tent and selective GGTase inhibitor, is in preclinical
development, and GGTI-2418 is in a Phase I clinical trial
for treatment of breast cancer and multiple myeloma
[47–52]. Our data here support selective inhibition of
GGTase as the mechanism of stain-induced CD55
upregulation in astrocytes. GGTIs may thus provide an
alternative approach to increase CD55 expression
without altering cholesterol biosynthesis. We note, how-
ever, that although a large body of literature supports
the safety of statins, the safety of drugs that target other
steps of the cholesterol biosynthesis pathway must be
demonstrated. In addition, there are theoretical adverse
effects of increasing complement regulator expression
such as impairment of immune surveillance in cancer.
The ability of drugs to cross the blood-brain barrier is
an important consideration in NMO therapy. The
A
B
C
D
Fig. 7 Atorvastatin reduces NMO pathology in an experimental animal model of NMO produced by passive transfer of AQP4-IgG. a Experimental protocol.
Mice received atorvastatin 20mg/kg/day for 3 days, or saline vehicle, prior to intracerebral injection of 7.5μg AQP4-IgG and 1 μL human complement. Mice
were sacrificed on day 6. b Immunofluorescence of AQP4, MBP, and Iba-1 in the brain at day 6 showing AQP4-IgG-injected hemisphere from control and
atorvastatin-treated mice. Representative of experiments on 4–5 mice per group. c Immunofluorescence of activated complement proteins C3d and C5b-9 at
day 6 from control and atorvastatin-treated mice. Representative of staining done on 4–5 mice per group. d Summary of lesion areas (AQP4, c5b-9, MBP, in
mm2) and Iba-1 cell positivity (positive cells per 0.01mm2), showing data from individual mice (mean± SEM, n=4–5, **P<0.01, unpaired Student’s t test,
compared with vehicle)
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penetration of statins into the central nervous systems
varies with their structure and lipophilicity. Lipophilic
statins (atorvastatin, lovastatin, fluvastatin, pitavastatin,
simvastatin) can penetrate the blood-brain barrier pas-
sively, while the hydrophilic statin pravastatin does not
[29, 30]. Among the lipophilic statins, lovastatin has
been reported in rat studies to best cross the
blood-brain barrier [29]. However, lovastatin and simva-
statin are inactive lactone prodrugs that require in vivo
hydrolysis to give the pharmacologically active form.
Atorvastatin is an active drug with high cellular and
blood-brain barrier penetration. Atorvastatin has been
reported to have neuroprotective effects in animal
models of brain pathology associated with neuroinflam-
mation, including traumatic brain injury and experimen-
tal autoimmune encephalomyelitis [33, 35]. Atorvastatin
has also been reported to have immunomodulatory ac-
tions involving alteration of T and antigen-presenting
cell (APC) function, and inhibition of immune cell inva-
sion [31–33]. These immunomodulatory effects of ator-
vastatin may be beneficial in NMO, apart from its action
on complement regulator expression.
An atorvastatin dose of 10 -20 mg/kg/day orally was
chosen here for in vivo mouse experiments. This dose
was based on pharmacokinetic data and prior studies of
neuroprotection in rodents in which 10–50mg/kg ator-
vastatin was needed to achieve similar plasma concen-
trations as in humans [30, 33–35, 53–55], in which the
maximum recommended daily dose is 80 mg/day, or ~
1–2 mg/kg. Atorvastatin may thus confer neuroprotec-
tion in humans at the typically used human doses.
Questions in targeting complement regulator proteins
for NMO therapy include which complement regulator
proteins to target and on what cell types and the magni-
tude of upregulation needed to confer clinical benefit.
There are available data regarding CD59 in NMO from
experimental animal models. Transgenic knockout of
CD59 greatly increases the susceptibility of mice and
rats to development of NMO pathology following pas-
sive transfer of AQP4-IgG into central nervous system
tissues [15, 17, 18]. CD59 upregulation by lentivirus is
associated with reduced NMO pathology [21]. Mathem-
atical modeling showed that theoretical increases in
CD59 expression could prevent cell swelling induced by
AQP4-IgG and human complement [37]. Upregulation
of CD55, but not of CD59, would inhibit the generation
of complement anaphylotoxins (C3a, C4a, and C5a), as
CD55 inhibits the assembly and accelerates the decay of
C3- and C5-convertase. Additional potential advantages
of upregulation of CD55 vs. CD59 for NMO therapy in-
clude the greater-fold increase in CD55 expression pos-
sible because of its low baseline expression compared to
CD59 and inhibition of a different step in the comple-
ment pathway and hence possible synergy with CD59.
Another theoretical advantage is the ostensible differ-
ence in the subcellular distribution of CD55 vs. CD59, as
CD59 has been reported to be expressed at relatively
lower levels in astrocyte end-feet where AQP4 is con-
centrated [56].
Though the data herein provide proof of concept for
the potential therapeutic utility of CD55 upregulation by
atorvastatin in seropositive NMO, several limitations are
noted. The demonstration of CD55 upregulation by ator-
vastatin in astrocyte cultures and mouse brain does not
ensure that clinically significant CD55 upregulation will
occur in NMO-affected tissues in humans at tolerated
doses of atorvastatin. As atorvastatin inhibits cholesterol
biosynthesis, the possibility exists, at least theoretically,
for inhibition of remyelination [57, 58], which might ac-
count for the inconclusive benefit of statin treatment in
multiple sclerosis [59]. Finally, upregulation of CD55 alone
does not target other effectors of NMO pathogenesis, such
as AQP4-IgG production and levels, antibody-dependent
cellular cytotoxicity, the peripheral complement system,
and T cell responses, though atorvastatin could be com-
bined with other currently used or investigational NMO
therapeutics such as immunosuppressants, plasma
exchange, complement inhibitors, and cell-targeted drugs.
Conclusions
In conclusion, pharmacological upregulation of comple-
ment regulator proteins such as CD55 represents a
novel approach for therapy of AQP4-IgG seropositive
NMO. Since upregulation of complement regulator
proteins does not interfere with the classical, alterna-
tive, or lectin complement pathways, the side-effect
profile might be relatively minimal. Upregulation of
CD55 expression by atorvastatin is predicted to not
only inhibit formation of the complement membrane
attack complex on astrocytes and nearby bystander
cells, but also inhibit the formation of complement ana-
phylotoxins that promote inflammation and cellular in-
jury. Clinical evaluation of atorvastatin in seropositive
NMO therefore seems warranted based on its estab-
lished safety profile and multiple potential beneficial
actions. Retrospective analysis of NMO patients
treated with statins for other indications may be in-
formative as well.
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